EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
May 16, 2024
Earnings Call Speaker Segments
Operator
operatorGood afternoon, everyone — or good morning, depending on where you're joining from — and welcome to the conference call covering El.En.'s financial results for the first quarter of 2024. This call is being recorded today, which means there will be a chance to ask questions once the conference call has ended. Joining me are Andrea Cangioli, El.En.'s CEO, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relations. Before we get started, please be aware that management will make remarks on this conference call regarding future expectations, plans and prospects, as well as forward-looking statements. A number of statements in this call — among them those dealing with the company's beliefs, plans, objectives, estimates, or expectations of possible future results or events — constitute forward-looking statements. Such forward-looking statements carry known or unknown risks, including general economic and business conditions and the conditions in the industry we operate in, and they may be affected if our assumptions prove to be inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements could differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding the content, nor to update the forward-looking statement to reflect events or circumstances that may arise after the date thereof. If you would like to ask a question, please book your question on the chat of Bianca Fersini Mastelloni.
Operator
operatorI'll be glad to bring you in according to the booking order, but right now I want to hand things over to Andrea Cangioli. Andrea, please go ahead.
Andrea Cangioli
executiveThanks, Bianca. Morning, everyone. Appreciate you being here on this earnings call following the Q1 2024 financials release. Enrico Romagnoli joins me on the line and, as he typically does, he'll walk through the financial reporting details. The results we published yesterday for Q1 of 2024 match what we expected, mirroring a pattern that began with the demand peak in mid-2022, then gradually normalized, shedding momentum step by step through 2023. Consolidated revenues came in at approximately EUR 149 million, a 7% decline versus 2023. EBIT reached EUR 14.3 million, 15.7% lower than 2023, representing 9.6% of revenues. The short version: during the quarter, sales volume was softer across both industrial and medical markets; shifts in sales mix delivered a higher gross margin; and greater expense in absolute terms for sales and marketing — plus, in relative terms, from reduced leverage — produced a lower EBIT margin and lower EBIT. Enrico will shortly give you the specifics on certain non-recurrent items that lifted gross margin and raised expense and accruals. In fact, at the EBIT line, one-time revenue and one-time expenses offset each other. As you may recall, 2023 opened brilliantly for us, and then the following quarters saw a steady deceleration.
Andrea Cangioli
executiveFor 2023—sorry, for 2024—the expectation built into the yearly guidance we delivered was, and remains, that we would bounce back from the initially slower start through gradual improvement across 2024. Before I give you more color and detail on how our main market areas are trending, I want to offer a few comments on the broader economic climate we're operating in today. It wouldn't be fair to say we're up against adverse market conditions, but it's clear that some events and situations casting a shadow over the brightness of the economic trend are turning out to be far more persistent than we had anticipated. I'm referring first of all to the level of interest rates. It was taken for granted that rates would be cut in the U.S. and Europe, but the event investors are awaiting in order to see a reduction in their lending costs keeps being put off again and again. And second, the wars—the Ukrainian one, still very uncertain in its results, and the knock-on effects on relations between the involved parties and their allies, of which we are really not part, and the same goes for the Middle East war, which is impacting an area that is very important for our medical business as well.
Andrea Cangioli
executiveAnd of course, because for the capital equipment market, strong confidence in what lies ahead plus low interest rates are greatly aiding investment decisions, we aren't currently in a phase where the overall trend favors investments. That said, broadly speaking, let's look at the different businesses, which run on fairly distinct market drivers and hence market conditions. In laser cutting, international markets keep presenting attractive sales opportunities for our products, whereas our two home markets, Italy and China, are struggling. We had a quarter that was flat in sales in China, where structural cost reduction let us improve the bottom line, and revenue and earnings fell sharply in the Italian market. Finally, we are expanding quickly in the international markets, where our offering faces softer competitive pressure and can therefore reach higher sales margin levels. In Italy, we are enduring the difficult situation created by the fiscal policies our government introduced to support investment in technologies. We knew the so-called Industry 4.0 tax cuts were expiring after the reduction in 2023, and we anticipated a slowdown in sales afterward, but we could not have expected that the following fiscal support package would be announced and promised yet not implemented — or rather, implemented without the necessary details on scope, amounts, and eligibility procedures.
Andrea Cangioli
executiveNear term, this gives one more reason for people to hold off on investment choices while they wait for the policy to be spelled out clearly. The encouraging part of this shift in geographic sales mix is that margin on sales got better. I'm still referring to the laser cutting business. After excluding the effects of the flood damages reimbursement proceeds — you'll find the detail in the report — that lifted the division's gross margin by 2.8 percentage points. Gross margin on sales at the laser cutting division rose 3 points, from 21.1% to 24.1%, versus Q1 2023. The laser marking business for identification and traceability keeps going through a very positive phase, driven by general market demand, but I'd also highlight, above all, the very consistent approach LASIT, the company in charge of this segment, has chosen for approaching the market. The project to internationalize distribution is paying dividends, leveraging the strategic goal of being closer to customers so as to identify their specific needs, and making use of the very structured and flexible facility at Torre Annunziata to give them the most effective customized solutions. LASIT and its subsidiaries posted a 17% revenue increase in the quarter, and they are accretive to consolidated margins on sales and margins as well.
Andrea Cangioli
executiveSo to round out the picture on the industrial side, just a few words on where our Chinese activities stand right now. The financial results were poor in 2023, and they're improving here in early 2024 — the bottom line is still red, but we expect to reach break-even over the next quarters, thanks to the effect of a reduced fixed cost basis and the progressive increase of higher margin bearing international revenue. ... Excuse me.
Andrew Lawford
analystMy apologies — would you mind repeating that, please?
Andrea Cangioli
executiveThe IPO that we’ve been working toward for a long time is now suspended, and it’s waiting for more favorable conditions to return. At present, the financial results don’t meet the standards — from either a Chinese regulatory standpoint or a business standpoint — to file a successful IPO. The private equity funds that had put money into Pentalaser, which is the mother company of the laser cutting division, with the goal of accompanying the company to the IPO, are exercising the withdrawal option reserved for them within the capital increase agreements. Talks are underway with the current private equity investors, and with other investors who could potentially replace them in supporting the company’s ambitions. Turning to our medical business, overall revenue was down 5%, mainly because of a soft performance on the aesthetic market, which in turn was mainly because of the soft performance of the hair removal business. In other aesthetic segments, like toning with Q-switched and picosecond lasers, mini ablative anti-aging, the sales volume was in line with last year. Most of the sales decline in hair removal is attributable to a weak demand from the United States. Two more comments about this trend: The first is that overall gross margin improved, since hair removal is the most competitive and lowest margin-bearing application in the segment.
Andrea Cangioli
executiveThe second point concerns what we offer in this segment as well as expanding and refreshing the product range, and that is really our key competitive tool. We've had a productive stretch for launches, with the biggest one being that the Pro Line of the DEKA systems for medical aesthetics is now complete. Through the Pro Line, customers get a palette of systems built on different technologies that deliver better performance and usability for body shaping, anti-aging, and hair removal. Additional products were designed specifically with US customers in mind, and they already carry the FDA clearance. I'm referring to hair removal devices with improved performance and a new revolutionary body contouring system. Each of these new systems is in its initial production phase, in step with or corresponding to its commercial launch. We hold a very interesting backlog that will underpin sales over the coming months, as soon as production volume for these models ramps up. Sales of surgical lasers again exceeded the same quarter a year earlier, led in particular by urology sales. In this segment too, a new product launch happened during the quarter, as Quanta System announced the Cyber Ho Magneto at the European Association of Urology Congress, and it will enable the most effective power delivery in stone management devices.
Andrea Cangioli
executiveThe final remark on sales ties to a pattern seen in both the industrial and medical segments. What we refer to as service sales are growing, and that category covers every revenue stream arising after a system is sold. This means technical maintenance service — whether set up on a time and material basis or under a service contract — plus consumables sales, where usage of the system mainly requires optical fibers for urological surgery, along with lamps and refurbishing for hair removal devices, and laser mix gas bottles for the semi-sealed CO2 laser sources used in industrial applications. Another point worth noting: service revenues rose far more in the industrial business than in medical, reflecting how quickly the installed base has expanded during recent years, with many systems now reaching the end of the warranty period. The one-time expense that weighed on our performance in Q1 2024 is the accrual booked at With Us, the Japanese company focused on the local professional aesthetic market. That market and that company had ranked among the group's most significant drivers of revenue and margins, though not in the recent past. The accrual accounts for the financial downturn experienced by our most significant customer, a chain of beauty salons dedicated to hair removal.
Andrea Cangioli
executiveThis situation is hurting what remains of our business in the professional aesthetic market in Japan — activity that, because of competitive pressure in that particular segment, had already been confined to servicing the installed base alone. We are looking at options for downsizing. On a consolidated basis, the impact of this event, together with its foreseeable consequences to date, will not materially change the business trend or the guidance. Cash flows were a subject for El.En. over the past year: the first half saw a strong trend of cash absorption, which the excellent cash generation of the second half then partly offset. Absorbing cash in the first half and generating it in the second is the seasonal pattern for our organization, and 2024 is no exception. The net financial position fell by EUR 8.5 million in the quarter, chiefly because of working capital dynamics — namely an inventory increase in preparation for a stronger Q2, and also down payments received from customers and paid to vendors. Capital expenditure was also somewhat above the quarterly average expected for the year, partly owing to a contingent IFRS 16 effect tied to renewal of a building rental contract. We regard this trend as physiologic and not a concern.
Andrea Cangioli
executiveWe don't anticipate the net financial position getting better in Q2 either. That's the quarter in which dividends go out to our shareholder and taxes go to our government, and we do expect improvement during the second half of the year. I'd also like to give a brief report on the activities we're carrying out in sustainability. The 2023 to 2027 five-year plan was drawn up, and it identifies specific, measurable sustainability activities and objectives regarding the fight against climate change, circular economy, economy, promotion of a responsible supply chain, valorization of people, and contribution to the community. This confirms the commitment to sustainable development and that environmental and social responsibility are becoming an integral part of the group's business model. We also launched the projects that will let us align with the reporting regulatory requirements by the end of this financial year. That's all for my introduction at this moment. I'd like to hand over to Enrico for the financial report.
Enrico Romagnoli
executiveThanks, Andrea. Good morning, everyone. As usual, I'll give you some details on our most recent financials. In Q1 2024, the group posted total turnover of EUR 149.5 million, a decline of 7% versus the 161.4 recorded in Q1 2023. ...The sales slowdown during the period was more pronounced in the industrial sector, at -10%, as the slide shows, than in the medical sector, at -5%. The impact on sales from the two sectors remains the same as last year. In 2024, weakness in foreign currency — mainly the US dollar, renminbi, yen, and again, the euro — had a cumulative impact on growth of approximately -1.2%, or -EUR 1.8 million in absolute terms. Gross margin came in at EUR 62.4 million, up 2.1% from the EUR 61.1 million in Q1, with an impact on sales of 41.7%. As Andrea already mentioned for the period, gross margin includes the other proceeds — the reimbursement obtained related to damages suffered from the Campi Bisenzio flood in November 2023 — amounting to EUR 1.9 million, equal to 1.3% of consolidated revenues. Even excluding this non-recurring income, the mix of products sold led to an improvement in sales margin from 37.9% to 40.4%.
Enrico Romagnoli
executiveIn fact, the removal application—the most consolidated one, yet the one with the lowest sales margin in aesthetics—saw its relative weight decline versus the other applications, just as surgery, which carries a better margin, gained weight. On the industrial side, the share of cutting, which bears a lower margin than the marking system, enabling sources that perform better in the period, went down. At the same time, the margin on sales in the laser cutting sector did improve, thanks to a greater incidence of sales outside Italy and China. Operating expenses rose as an impact on sales, from 8.7% to 10.6%, and the main driver is sales and marketing expenses for trade fairs and congresses, encouraged by both the medical and industrial companies. The number of international trade fairs and conferences in which the group took part in the first month of the year was significant and above average. Staff cost increased by EUR 1.1 million, +4.4%, rising as an impact on sales from 16.2%-18.2%, due to the lower turnover recorded in the period. As for 1.4 percentage points, the increase in personnel cost is determined by the rise in national cost for stock option plans for employees, equal to EUR 856,000 in the period, compared with the EUR 453,000 in the Q1 of 2023.
Enrico Romagnoli
executiveWhen it comes to EBITDA, we posted a positive figure of EUR 19.2 million, which represents a decline of -8.2% against the EUR 20 million recorded in Q1 2023. The EBIT margin for Q1 came in at 12.9%, matching the 13% seen in Q1 2023. BIT for the quarter was positive at EUR 14.3 million, lower than the EUR 17 million posted in Q1 2023. Its margin on revenues stood at 9.6%, a slight dip from the prior year, when that margin was 10.6%. The EUR 1.6 million provision for credit risk that our Japanese subsidiaries set aside — following the financial crisis at its most important customer that Andrea mentioned — had a significant impact on quarterly EBIT and, in fact, offset the positive effect proceeding from the reimbursement received for the flood. The impact of these accruals is 1.1% on EBIT margin. Within net financial income, we recorded EUR 187,000 of income, versus a loss of EUR 459,000 booked in the same period of last financial year. That improvement is essentially due to the more favorable effect of currency exchange rates during the period. Income before taxes showed a positive balance of EUR 14.4 million, a 13.3% decrease compared with the EUR 60.6 million of Q1 2023.
Enrico Romagnoli
executiveOn cash flow, the group's net financial position stayed broadly positive at EUR 46.2 million, versus EUR 54.6 million as of December 2023, a drop of EUR 8.4 million. Net working capital growth took in EUR 9 million, and EUR 10 million went into the shift in other short-term assets and liabilities, which covers the rise in advances paid to suppliers, the fall in advances received from customers, and the growth in VAT credits owed by the Italian treasury stemming from higher exports. CapEx for the period came to EUR 5 million. EUR 1.5 million of that went to expansion of reorganization works at the manufacturing plants, with the same amount for equipment, vehicles, and other assets. Another EUR 1.5 million came from booking new investment tied to accounting for rental fees under the IFRS 16 standard, which affects the net financial position but not the liquid position. Looking at revenue by business, in the medical sector the positive phase of surgical application carried on, up 4% in the quarter, with EUR 20 million in revenue, driven above all by urology systems. Aesthetics, with turnover of EUR 48.4 million against EUR 55.6 million in Q1 2023, showed a decline of 13%, which narrows to 10% when service revenue pertaining to the aesthetics itself is included.
Enrico Romagnoli
executiveAfter-sales service and consumables turnover grew 7% again, driven by urology laser system usage. Optical fibers are helping revenue trend positively in medical service, which posted EUR 19.91 million in sales versus 17.8 in Q1 2023. The therapy segment, run by ASA of Vicenza, with EUR 3.7 million in revenue, saw a slight revenue decrease this quarter, -5%, versus EUR 3.9 million in Q1 2023. In industrial, laser cutting — which had posted a long stretch of growth quarters in recent years — showed the most pronounced drop, -15%, with revenue at EUR 44 million versus EUR 51.7 million in Q1 2023. The laser cutting business unit, including the related portion of service revenue, posted total turnover of EUR 47.8 million versus 54.3 million in Q1 2023, down 12%, and EBIT of +EUR 1.2 million versus -EUR 1 million in Q1 2023. Q1 2024 EBIT includes EUR 1.2 million in non-recurring proceeds, part of the EUR 1.9 million reimbursement for the fraud mentioned earlier. Turnover from Chinese activities stayed broadly in line with 2023 levels, limiting losses thanks to structural cost reduction and margin improvement from increases outside China.
Enrico Romagnoli
executiveTurning to marking: turnover came in at EUR 6.4 million against EUR 6.7 million for the same period in 2023, so that segment was down, with a soft quarter in decoration application — partly reflecting the broad difficulties the fashion system faced during the period — while the identification and traceability systems business unit, run by LASIT of Torre Annunziata, grew. After-sales service revenue shows a notable pickup, +24.3%, with sales of EUR 6 million versus EUR 4.8 million in 2023, which is directly tied to how quickly the installed base has expanded. We were very pleased with how medium-power laser source sales performed, up 12%. Sales by area. Looking at sales by macro geographic area across the two sectors, foreign markets again outperformed Italy. Specifically, medical sector sales are down 5%, chiefly because of a decline in the Italian market. Industrial sector sales were hit above all by weakness in Italy and, to a smaller degree, in Europe, while posting a recovery in the rest of the world, helped by a stable Chinese market, excellent results at the Brazilian subsidiaries, and the rapid acceleration of the U.S.
Enrico Romagnoli
executiveAndrea, you have the floor now to walk us through the guidance.
Andrea Cangioli
executiveThank you. So, to wrap up: with the guidance, as you've seen in our press release, following Q1 we are essentially reaffirming the annual guidance, which indicates growth in both revenues and EBIT versus 2023. When we first issued that guidance, we already factored in — and here we are, two months later — what we have observed shifting during this period. We remain confident about the recovery versus 2023 across the remaining quarters of this year, yet some macro trends that were meant to underpin that recovery — specifically, interest rate cuts and the easing of international and regional unrest tied to the wars — are taking longer to materialize than anticipated. That is precisely the reason — and not the weaker results posted in Q1 — why reaching the guidance target is now more difficult than we believed two months ago. Bianca, that concludes my prepared remarks, and I'm ready to take questions.
Operator
operatorAll right. All right, and we have three people on the list. The first one is Giovanni Selvetti from Berenberg Bank. Please go ahead, Giovanni. Thank you.
Giovanni Selvetti
analystHi, everyone, and thank you for taking my questions. I have several. The first concerns the Chinese market. Your press release mentions sales largely in line with last year, with losses that were contained. As I remember, in the previous quarter, once you excluded the effect of the legal costs, China had returned to a positive EBIT. So I'm trying to understand the operating leverage here. Basically, what amount of sales do you need in China to break even? Still on China, you say the balance of bank and postal deposits of the Chinese company includes roughly CNY 7.5 million of deposit banking, the issuance of bank bills for payments. What exactly does that mean? The third one is, perhaps Enrico mentioned it earlier and I missed it, so could you please quantify the expense for exhibitions and fairs in Q1? And then I think the other one is more about the guidance. So I suppose today's performance is really about what consensus read as a slow start to the year. So to avoid confusion, are we talking about the rebound in Q2?
Giovanni Selvetti
analystWould a sales rebound come in at 3, 4, or 5%? I just want a feel for what to expect in Q2 of this year and therefore for the first half. And my genuinely final one is broader in nature, though perhaps you can also shed light on why Italy has been weak. There has lately been some speculation that Prima Industrie and Salvagnini want to create an Italian main player in laser cutting. So the questions are two: do you see more competition there? And three, if they truly intend to build a national player, would you think about selling? That's... I have finished with the question.
Andrea Cangioli
executiveAlright, first question — China. In Q4 we came near break-even, though an accrual pushed us under break-even in Q4 — sorry, in 2023. Q1 is seasonally a light quarter, particularly in China, since the New Year's festivity hits the country, and so you typically see the weakest leverage effect on sales. Because of that, having improved but not reached break-even in China is of course unsatisfying, yet it confirms we're on track to hit break-even on a yearly basis, since Q1 brings reduced revenues. Give me a second and I'll try to answer in more detail. Essentially, China revenues for the quarter came in at just over EUR 20 million. Given current margins, I think we need roughly 20% more — 20% to 25% more, meaning closer to between EUR 25 million and EUR 30 million in revenue — to reach break even. Naturally, that break-even level drops as sales in the international market rise, and those, as I said, carry higher margins. That's question number 1. Question number 2 is basically — maybe I'll try to explain, and then Enrico, if I'm wrong, you'll get it better.
Andrea Cangioli
executiveBecause we're paying suppliers with certain notes, the bank is keeping some of our bank deposits in escrow, in a way, until those notes get paid.
Enrico Romagnoli
executiveYes.
Andrea Cangioli
executiveThe expense associated with exhibitions.
Enrico Romagnoli
executiveRegarding the exhibition—if you're looking at sales and marketing broadly for Q1 2024, that included Congress, plus trade fairs, travel costs and so forth—we're talking about more than EUR 5 million, specifically EUR 5.1 million, versus EUR 4.5 million in Q1 2023.
Andrea Cangioli
executiveThanks, Enrico. Appreciate it, Enrico.
Enrico Romagnoli
executiveAppreciate it.
Andrea Cangioli
executiveOn the short-term guidance, it's difficult for me to give you a sense of that, since what I'm confirming here is the midterm guidance. I can't tell you. I'm sure we'll see the Q2 financial results of 2024 improve versus Q2 2023, but I'm not in a position to give you a number, a number on that. Regarding Italy, the reason for the strong slowdown in Italy is mainly driven by the industrial market, but we slowed down in the medical market as well. Basically, I think I gave a fairly extensive description of the situation of the Italian market for manufacturing investments in early 2024. We were expecting a slowdown because the Industry 4.0 is losing its effect. We have several customers procrastinating investment decisions, waiting for the rules for the 5.0 new tax cuts to be finally disclosed in detail. As you know, the 5.0 is in place, but the details on how you file and how you get the monies and what you actually have to do are still uncertain. This, in a situation in which the market is not strong, because we are not in a situation of strong market, has slowed down the investment decision. For what concerns the medical market in Italy, we are in a situation which is normal.
Andrea Cangioli
executiveWe did experience a deceleration, particularly in the aesthetic segment—within aesthetics. We remain reasonably confident that the situation can, in any case, be sustained at solid revenue levels, with solid margins and solid profitability for the activity in Italy too. Regarding the Prima and Salvagnini transaction, we are familiar with the two parties involved in this prospective deal. We think they have sound reasons to merge, given that they complement each other across several of the businesses they operate in. I mean, they... Should the deal be confirmed, they would create a single entity of roughly EUR 1 billion in revenues, taking into account as well the revenues Prima generates through its Finnish structure. They pose no threat to us competitively for what they do today, because the El.En. Group is broadly complementary to both Prima Industrie and Salvagnini, as we compete mainly on two-dimensional laser cutting systems, while Prima focuses mainly on three-dimensional cutting and has a very, very weak presence in two-dimensional cutting. And we are complementary, because we hold a significant production base on Chinese territory, which is something both Prima—that attempted it but never truly managed to establish a real stronghold in China—and Salvagnini lack.
Andrea Cangioli
executiveAlso, Salvagnini has no plant in China. It's worth noting, by the way, that the two of us are complementary — particularly with respect to Salvagnini — and in the direction we're moving, which is bringing our 2-D laser systems into manufacturing cells, manufacturing cells, or bigger manufacturing factories that cover not just laser cutting but also handling of the cut pieces, storage, and nesting of the parts — in a word, automation. On Chinese soil, we've worked together with Salvagnini on a handful of very good deals.
Operator
operatorAndrea?
Andrea Cangioli
executiveSi.
Operator
operatorCarlo Maritano from Intermonte has one more question for us. Carlo, please go ahead.
Carlo Maritano
analystGood afternoon, everyone. I’ve got a couple of questions. First, a clarification on guidance. You said the current situation makes it difficult to maybe hit the initial targets. But do you still expect to grow in terms of, say, EBIT this year, or do you expect EBIT to be flattish or negative compared with last year? That’s the first question. The second is on the industrial business, especially in Italy. You’ve already partly answered my question. So with the delay in Industria 5.0, do you expect it to last for at least a couple of quarters and to see some revenues by the end of the year? Or do you expect a longer term before we start to see revenues from these incentives? The final one is on the services business. So as you mentioned during the presentation, this is growing thanks to the increase in the installed base. So do we have to expect in the future that the incidence of services will grow given that the installed base is growing? So do you expect it to account for more than 10 to 13% of revenues in the future? Thank you.
Andrea Cangioli
executiveLet's begin with the question about guidance. So we confirm that our guidance is to beat 2023, both in revenue and in EBIT. We add that it's harder today as an objective than it looked like two months ago. About the expectation on the Italian market, we are positive in general, but this is completely detached from the 5.0. What I wanted to mention is that while, of course, we can attribute part of the success, especially in the year 2022, of the sales of manufacturing devices to the existence of Industry 4.0, today, the fact that nothing is clear about Industry 5.0 is simply procrastinating the investment decision to the point that I'm saying that today it would have been better if there was no expectation for such a tax cut, because, if there were no expectation to have future tax cuts, people would have invested because there was no reason to wait. And this, in this moment, they wait for something which could be also quite complex, especially for smaller investment to achieve, because as you might know, the 5.0 includes adding to the 4.0 requirements, also the power supply reduction, the power consumption reduction, which is complex, not only in achieving it technically, but also in documenting it.
Andrea Cangioli
executiveSo the investor has to bear a cost to demonstrate that the investment is producing a reduction in power consumption, and because of that, the incentive offered by the 4.0 and 5.0 will end up smaller, given the expenses tied to proving it — to the proofing of this. And then the other, the third question, about the service business. The service business — yes, broadly speaking, broadly speaking, and we see this clearly in the industrial business, where the installed base has grown very quickly over the last two years. And we observe it with a slight lag as the installed base rises, because those units are covered by warranty for a certain period. Now, the system leaves the warranty period, and they begin generating revenues. So the statement holds for the general trend of technical service. So if the service line were technical service only, the answer would clearly be yes, it will grow, and its share will grow. The point is that within our service aggregate, we do not have service as technical service revenue alone, but we also have consumable revenue, and consumable makes up quite a significant portion of these service revenues.
Andrea Cangioli
executiveWhen it comes to this, the trend isn’t always linked to the installed base; it’s also linked to how that installed base is used for the particular application that requires the consumable, and to whether alternatives to the consumables our group supplies are available on the market. We can’t necessarily lock customers into using the consumable we provide, but in certain circumstances, some customers can buy their consumables themselves. Broadly speaking, the answer to your question is yes, but there are certain considerations, given the actual makeup of the sales aggregate we call service.
Carlo Maritano
analystThat’s very clear, thank you.
Operator
operatorAndrea, question number three is from Andrea Bonfa at Banca Akros. Andrea, please go ahead.
Andrea Bonfà
analystGood afternoon, everyone. I have a couple of questions. The first concerns how the industrial laser business grew in the rest of the world. Could you expand a bit more on that 30%+ increase — is that China versus the rest of the world, and which countries are involved? Clearly Italy versus the rest of the world as well, and again, which countries? I'm also curious about the contribution in the Arab Brazil and in the U.S., a market you targeted in the past. And the second one: could you repeat the EBIT performance of the industrial laser business? I'm not sure I quoted it very well — was it minus 1.2 or plus 1.2 — and what was the component there of the Nordic Harin, if I have that right? Thank you.
Andrea Cangioli
executiveTo start with, on sales outside the non-domestic segment — with domestic being Italy and China — Brazil grew quickly. In Brazil we posted record sales, as we did in the US, and these are the markets where we performed very strongly among the Western markets, and then we also did well in Korea and Australia for the markets that China serves. On your second question, I don't believe I provided any EBIT figures. What I believe I provided was some gross margin information.
Andrea Bonfà
analystAnd as for Puerto Rico —
Enrico Romagnoli
executiveYes, I did. I handed over the—
Andrea Bonfà
analystAh, .
Enrico Romagnoli
executiveOkay. So, regarding the cutting business unit — I’m referring to the cutting business unit. What I’d say is that, relative to Q1 2023, in Q1 2024 we recorded positive EBIT of EUR 1.2 million, and that EUR 1.2 million — the contribution to this EBIT — comes from EUR 1.2 million in non-recurring proceeds. Therefore, if you exclude those non-recurring proceeds, the reimbursement for flood damages in November 2023, the business unit’s EBIT was zero, versus minus one million in Q1 2023.
Andrea Bonfà
analystUnderstood. Thanks a lot, Enrico and Andrea.
Andrea Cangioli
executiveThanks, Andrea. Goodbye. All right. Bianca?
Operator
operatorYes. Our next question is from Andrew Lawford at Fund Scouting. Go ahead, Andrew. Thanks.
Andrew Lawford
analystThanks, Bianca. I have a quick follow-up on service revenue, which you already touched on. What I saw is that, measured against sales, it grew when we compare Q1 with what you did in 2023. Is that a trend? I mean, do you think it could approach, let's say, 20% of revenue? And if you could also maybe speak to the margin dynamics of service revenue. Should we generally expect service revenue to carry a higher margin, or does it once again hinge on the distinction you drew between technical service and the consumables? Thank you.
Andrea Cangioli
executiveAll right. If we hold the consumables revenue ratio steady, then service revenues should have a growing effect—let's say—on boxes and on systems revenues. It could go higher. My sense is we're already at a fairly high level, a fairly high level. On margin, it's more or less comparable to what we get on system sales, so there isn't much of a gap, because, as I told you, as I said when discussing, for example, optical fiber sales, we aren't necessarily on our own. Customers aren't captive, so we can't freely set prices at whatever margin we'd like; instead we have to stay at market prices, and thus market margins, so that we don't lose that revenue to alternative suppliers who might be coming into our customer base to sell their consumable devices.
Andrew Lawford
analystAll right, thanks.
Andrea Cangioli
executiveGlad to help.
Operator
operatorOur final question is from Lorenzo Capellotto at Praude Asset Management. Lorenzo, you have the floor.
Lorenzo Capellotto
analystHello, and thanks for taking my question. I actually have a few. First, from what I understand, you said the Q1 slowdown was mostly because of the incentive issue — specifically, the 4.0 came to an end and there was an unclear picture around the 5.0. But if that's the case, why did every one of your sectors, medical included, decline in Q1? Could you explain a little better what drove the medical segment to also perform poorly? My second question: I see labor costs rising quite substantially, so I'm wondering whether you're having trouble hiring new people and attracting new talent. If you could give a bit of explanation on that front, that would help. And finally, the worst performer in Q1 was, of course, the cutting segment — so on that front, is the slowdown due only to market factors, or to a weakness in the sector, or are you facing greater competition from rivals such as Chinese and Turkish players, which as far as we know keep growing and are putting pressure on you? That's all from my end.
Lorenzo Capellotto
analystThanks.
Andrea Cangioli
executiveAlright. I'll begin by responding to your first question, and that response also covers the third one. When I say that the wrap-up of 4.0 and the gradual arrival of 5.0 is causing our sales to slow, I'm referring to exactly one market: Italy's market for industrial applications. 4.0 doesn't apply to medical applications, nor does it apply outside Italy, so what I'm really saying is that the region where the slowdown hit us hardest — Italy, where business contracted — was likewise impacted by the incentives situation, and that part is specific. As for the remaining slowdown, I framed it as a gradual deceleration that we saw starting in the opening months of 2023, which essentially brought demand pressure back to normal after the peak we had in 2022. The early months of 2023 went well, still carried by the momentum of that exceptional demand — the rebound following the COVID period that occurred in 2022. After that, things normalized, and we've observed this normalization weighing on our sales volume through a slow comparative decline versus prior years across the different quarters. And we've observed that order bookings would have resulted in lower revenues in Q1 of 2024 across the board, in, in roughly every segment.
Andrea Cangioli
executiveNaturally, there are exceptions, yet as the overall revenue envelope, we had observed it. We had likewise observed that order booking, at least for our company, had reached what you might call a floor at the close of 2023, and then order booking grew stronger once more at the start of 2024, which lets us project revenue growth across all of 2024, stemming from this larger volume of order bookings, and also from the fact that in the quarters ahead we will be up against a less demanding comparison in the 2023 results. Regarding the rise in expense for staff, for employees, naturally, we were planning. We always plan a midterm expansion of our sales and production volumes. To support those, we must bring in people in R&D, in production, across all the functions. After three years and two years of rising revenues, we likewise raised the count of employees, aside from certain exceptions. So, once you raise employees over a year, when you, at the start of the next year, compare the expenses for employees against the initial expense of the year, you invariably get what you would call a comparison that reveals an increase.
Andrea Cangioli
executiveThat ties into what you raised as well. We need to keep a close eye on the overall well-being of a number of employee groups, since the market—particularly for certain types of workers—keeps getting more competitive. That pushes our employee costs higher, and it also puts pressure on everyone's general welfare, which means we must give them things like environmental support so the roles they hold within our group become more and more appealing. So the issue you brought up does exist. I want to say that we see this problem quite clearly, and we think we have the right policies in place to secure and ensure that personnel of the right caliber remain in the group—a group that depends on the quality of its technicians, its designers, and its engineers in order to keep enhancing its product range and to grow through its capacity to innovate.
Analyst
analystMay I add one more question?
Andrea Cangioli
executiveSure.
Lorenzo Capellotto
analystOn the question of rivalry coming from China, Turkey, and… Would you mind giving that a little more color, please?
Andrea Cangioli
executiveOf course. Competition from China is, naturally, a theme and a topic. We all read the papers. When we read that Fiat will sell Chinese cars — or rather, that Stellantis will sell Chinese cars — that means local production players don't feel capable of competing against local production. Competition arriving from Far East countries has always been a theme in our market. Chinese manufacturers' competition is very strong in China as well. I mean, we are Chinese manufacturers for the industrial market, but we are struggling in China as well. But the international markets are typically more articulated. Especially in industrial, we deal with a fairly large market, on which we can compete in certain niches, in certain niches, where we are able to maintain certain margins. In a way, our very, very fast growth in the past was accomplished also thanks to the fact that our product was somehow commoditizing, and we took advantage of being part of a business where the product was commoditizing and becoming cheaper because the market was becoming much larger. When the market becomes too commoditized, a manufacturer — a small manufacturer compared to the larger size of certain competitors — loses competitive advantage unless it concentrates on certain niches where it can maintain the advantage of providing products that have superior characteristics, both in technical specification and in service provided to the customer, compared to the low-cost Far East competitors.
Lorenzo Capellotto
analystAre there other nations out there that compete with you — Turkey, as I brought up, for instance — or do they simply not factor in?
Andrea Cangioli
executiveNo, no—Chinese makers of laser cutting systems operate all over the world. We too, being a Chinese producer of laser systems, sell globally as well. What matters is this: generally speaking, Chinese manufacturers compete at a lower price point, in a lower market, a lower market area. Our competition happens at a higher price point and a higher market area. The same holds true when we sell within the same geographic market products we build in China and products we build in Italy. Theoretically, let's say, they do compete, yet in reality they aren't competing within the same market segment, since someone who wants an Italian-made laser system—with Italian cost and Italian performance, Italian services—is typically not interested in purchasing a Chinese-made laser system.
Lorenzo Capellotto
analystRight, right, I get that — but what I was asking is whether other countries that are just as competitive as China are coming into this market. Something like Turkey, maybe, or Poland — I don't know.
Andrea Cangioli
executiveRight, right. You brought up today that China, Italy, and I think probably Turkey are the markets where competition is toughest. That's also because in each of those markets there are local players who have done a good job of opening things up, and now Chinese competitors are coming into the market as well.
Lorenzo Capellotto
analystAll right, I appreciate you giving me the time.
Andrea Cangioli
executiveOh, thanks for those questions.
Operator
operatorAndrea, there's another question coming from Ludovico Latmiral at Samita Investing. Since he's having a technical issue with his microphone, I'll read it on his behalf. The question is this: "Could you also provide some commentary on how cash flow evolved across the full year? And should we anticipate a reversal in working capital from where it currently stands?"
Andrea Cangioli
executiveYes, I’m able to comment, and I can verify that, for the full year, the forecast is to produce cash for our internal programming reason and for the dynamics, the seasonal dynamics. Usually, the first quarter and Q2 are the biggest cash absorbers in the year. There are reasons that are slower, lower sales volume in Q1, dividend payout in Q2, higher record sales, let’s say, on the year in Q4, which allocate most of the cash generation in the second half. For this reason, we note the cash consumption of Q1, but we are confident that, given the trend that we expect on the year, we will return to cash generation in the next quarters, not in the second, but in the third and in Q4, and for the full year.
Operator
operatorHold on one second, Andrea. I’m checking with Lorenzo whether that’s truly everything you need in order to answer. All right, that works for you and for Ludovico. So right now, we don’t have any further questions. I just want to check with the floor whether any additional questions are there. Anything else? In that case—
Andrea Cangioli
executiveThanks. Appreciate it, everyone.
Operator
operatorThanks. I really appreciate you—
Andrea Cangioli
executiveThanks, thanks. We’ll hold for everyone on the 30th here in Florence. Matyaka, perhaps you could remind us.
Operator
operatorYes. Christopher, perhaps—Christopher, is there something you’d like to ask?
Lorenzo Capellotto
analystNope, I'm good. I'm good. I'll be coming by to see you before long anyhow, so...
Operator
operatorAlright.
Andrea Cangioli
executiveAlright.
Operator
operatorAlright. Thanks a lot, everyone, for joining the call. Bye. Bye.
Andrea Cangioli
executiveThanks. Goodbye.
Operator
operatorLater.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.